We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.52 | -1.63% | 91.56 | 91.54 | 91.56 | 94.03 | 91.45 | 93.99 | 315,477 | 10:34:39 |
From May 2019 to May 2024
By Michael Dabaie
Verastem Inc. (VSTM) said Thursday it is in a licensing agreement with Sanofi (SNY).
The agreement is for biopharmaceutical company Verastem's Copiktra for the treatment of all oncology indications in Russia and CIS, Turkey, the Middle East and Africa.
Shares were up 7% after hours to $1.40.
Verastem will receive an upfront payment of $5 million and can receive up to an additional $42 million in development and sales milestone payments, plus double-digit percentage royalties. Sanofi will receive exclusive rights to develop and commercialize Copiktra, and hold the marketing authorization and product license for Copiktra, in the licensed territories.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 25, 2019 17:16 ET (21:16 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
